Head and neck cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:21:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Head and neck cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing Two Treatment Lengths of Cetuximab, Avelumab, Cisplatin, and Docetaxel for Patients with Returning Spread Head and Neck Cancer https://clinicaltrials.eu/trial/comparing-two-treatment-lengths-of-cetuximab-avelumab-cisplatin-and-docetaxel-for-patients-with-returning-spread-head-and-neck-cancer/ Thu, 30 Apr 2026 13:08:30 +0000 https://clinicaltrials.eu/trial/comparing-two-treatment-lengths-of-cetuximab-avelumab-cisplatin-and-docetaxel-for-patients-with-returning-spread-head-and-neck-cancer/ This study is looking at recurrent metastatic head and neck cancer, which means cancer that started in the head and neck area and has either come back after treatment or has spread to other parts of the body. The study will use a combination of medications given through infusion into a vein. These medications include cetuximab, which is an antibody that targets cancer cells, avelumab, which is an antibody that helps the immune system fight cancer, and two chemotherapy drugs called cisplatin and docetaxel. Some patients may receive carboplatin instead of cisplatin depending on what is most suitable for them. The purpose of the study is to compare quality of life at 18 weeks after starting treatment between patients who receive two cycles of this combination therapy versus those who receive four cycles.

Patients in the study will be randomly assigned to one of two groups. One group will receive two cycles of the combination treatment, while the other group will receive four cycles. A cycle is a period of time during which the medications are given according to a specific schedule. All patients will receive the same medications, but for different lengths of time. The study will measure how the treatment affects quality of life, particularly how well patients can perform their daily activities and roles. Treatment can continue for up to 104 weeks depending on how the cancer responds and how well the patient tolerates the medications.

The study will also look at other important measures such as how long patients live without their cancer getting worse, how long patients survive overall, how many patients have their tumors shrink or disappear, and how long the response to treatment lasts. Patients will be asked to complete questionnaires about their quality of life and stress levels throughout the study to help researchers understand how the different treatment durations affect their daily lives and well-being.

]]> Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment https://clinicaltrials.eu/trial/study-of-eftilagimod-alpha-and-pembrolizumab-for-patients-with-advanced-head-and-neck-cancer/ Wed, 29 Apr 2026 15:00:48 +0000 https://clinicaltrials.eu/trial/study-of-eftilagimod-alpha-and-pembrolizumab-for-patients-with-advanced-head-and-neck-cancer/ This clinical trial focuses on treating patients with metastatic head and neck squamous cell carcinoma (HNSCC), a type of cancer that has spread beyond its original location and cannot be cured with local treatments. The study examines a combination therapy using two medications: pembrolizumab (also known as KEYTRUDA) and eftilagimod alfa (also known as IMP321).

The purpose of this research is to evaluate how well these two medications work together compared to using pembrolizumab alone in treating head and neck cancer. Pembrolizumab is given through an intravenous infusion into a vein, while eftilagimod alfa is given as an injection under the skin (subcutaneous injection). The treatment period can last up to 24 months.

During the study, participants will be divided into groups, with some receiving both medications while others receive only pembrolizumab. The medications work by helping the body’s immune system fight cancer cells. Doctors will monitor how the cancer responds to treatment through regular medical examinations and imaging tests.

]]> Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-tisotumab-vedotin-pembrolizumab-and-platinum-drug-combination-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:57:05 +0000 https://clinicaltrials.eu/trial/study-of-tisotumab-vedotin-pembrolizumab-and-platinum-drug-combination-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying the effects of a treatment called tisotumab vedotin on patients with locally advanced or metastatic solid tumors. These are types of cancers that have spread from their original location to other parts of the body. The study aims to evaluate how well tisotumab vedotin works on its own and in combination with other treatments. In some parts of the study, tisotumab vedotin is combined with pembrolizumab, a medication that helps the immune system fight cancer, and a platinum agent, which is a type of chemotherapy drug.

The study is divided into several parts. In some parts, patients will receive tisotumab vedotin alone, while in others, it will be given alongside pembrolizumab or both pembrolizumab and a platinum agent like cisplatin or carboplatin. These medications are administered through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will observe the effects of these treatments over time to understand their impact on the cancer and any side effects that may occur.

The purpose of this study is to assess the antitumor activity of tisotumab vedotin and its combinations in treating these advanced cancers. The study will monitor how the tumors respond to the treatment, how long it takes for a response to occur, and the overall survival of the patients. This information will help determine the effectiveness and safety of the treatment options being tested.

]]> Study on the Safety and Effects of Durvalumab and Tremelimumab with Radiotherapy for Patients with Metastatic Squamous Cell Carcinoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-durvalumab-and-tremelimumab-with-radiotherapy-for-patients-with-metastatic-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:27:31 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-durvalumab-and-tremelimumab-with-radiotherapy-for-patients-with-metastatic-squamous-cell-carcinoma/ This clinical trial is focused on studying a type of cancer called metastatic squamous cell carcinoma, which can occur in areas such as the head and neck, lungs, esophagus, cervix, vagina, vulva, or anus. The study is testing a combination of treatments to see how safe and effective they are. The treatments being tested include two medications: Durvalumab (also known by its code name MEDI4736) and Tremelimumab. These medications are given together with a type of radiation therapy called stereotactic body radiotherapy (SBRT), which is a precise form of radiation treatment.

The purpose of the study is to evaluate the safety and clinical activity of these treatments when used together. Participants in the study will receive the medications and radiation therapy, and their health will be monitored to see how their cancer responds to the treatment. The study will also look at any side effects that may occur. The trial is divided into two phases: the first phase focuses on safety, while the second phase looks at how well the treatment works in reducing cancer outside the area that receives radiation.

Throughout the study, participants will undergo various medical assessments, including imaging tests like CT scans, to track the progress of their cancer and any changes in their condition. The study aims to provide valuable information on the potential benefits and risks of using Durvalumab and Tremelimumab in combination with SBRT for treating this type of cancer.

]]>